News coverage about OptiNose (NASDAQ:OPTN) has trended somewhat positive on Tuesday, Accern reports. Accern rates the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. OptiNose earned a coverage optimism score of 0.07 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.8847466772343 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Shares of OptiNose (OPTN) traded down $0.41 during midday trading on Tuesday, hitting $16.95. The company had a trading volume of 10,053 shares, compared to its average volume of 51,801. OptiNose has a twelve month low of $15.01 and a twelve month high of $21.50.
Separately, Piper Jaffray Companies set a $28.00 price target on OptiNose and gave the stock a “buy” rating in a report on Monday, January 15th.
WARNING: “OptiNose (OPTN) Earns Daily News Impact Rating of 0.07” was first posted by BBNS and is owned by of BBNS. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://baseballnewssource.com/2018/03/13/optinose-optn-earns-daily-news-impact-rating-of-0-07/2023713.html.
OptiNose, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other.
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.